Immunwork’s TE-8105 Receives Australian HREC Approval and Officially Enters Phase 2b Clinical Development — Advancing to the Next Stage of Clinical Efficacy and Dosing Strategy Evaluation
T-E Pharma’s subsidiary, Immunwork, Inc., announced that its proprietary ultralong-acting GLP-1 receptor agonist (GLP-1 RA), TE-8105, has received approval from
